Larry Robbins's TMO Position Overview
Larry Robbins (via Glenview Capital Management, LLC) currently holds 282.9K shares of Thermo Fisher Scientific Inc. (TMO) worth $137.23 M, representing 3.05% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Larry Robbins has maintained a long-term strategic position in TMO, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2015, adding 2.3M shares. Largest reduction occurred in Q1 2015, reducing 4.5M shares.
Analysis based on 13F filings available since 2013 Q2
Larry Robbins's Thermo Fisher Scientific (TMO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Thermo Fisher Scientific (TMO) Trades by Larry Robbins
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +8.51 M | Add 0.00% | 8.51 M | $84.63 |
| Q3 2013 | -425,000 | Reduce 4.99% | 8.08 M | $92.15 |
| Q4 2013 | +451,432 | Add 5.58% | 8.54 M | $111.35 |
| Q1 2014 | +1.03 M | Add 12.02% | 9.56 M | $120.24 |
| Q2 2014 | +1.38 M | Add 14.45% | 10.94 M | $118.00 |
| Q3 2014 | +433,474 | Add 3.96% | 11.38 M | $121.70 |
| Q4 2014 | +11,598 | Add 0.10% | 11.39 M | $125.29 |
| Q1 2015 | -4.48 M | Reduce 39.31% | 6.91 M | $134.34 |
| Q2 2015 | +2.35 M | Add 33.99% | 9.26 M | $129.76 |
| Q3 2015 | -748,506 | Reduce 8.08% | 8.51 M | $122.28 |
| Q4 2015 | -2.58 M | Reduce 30.29% | 5.93 M | $141.85 |
| Q1 2016 | -2.32 M | Reduce 39.15% | 3.61 M | $141.59 |
| Q2 2016 | -752,312 | Reduce 20.84% | 2.86 M | $147.76 |
| Q3 2016 | -171,924 | Reduce 6.02% | 2.69 M | $159.06 |
| Q4 2016 | +973,418 | Add 36.24% | 3.66 M | $141.10 |
| Q1 2017 | -687,674 | Reduce 18.79% | 2.97 M | $153.60 |
| Q2 2017 | -212,095 | Reduce 7.14% | 2.76 M | $174.47 |
| Q3 2017 | -31,138 | Reduce 1.13% | 2.73 M | $189.20 |
| Q4 2017 | +598,749 | Add 21.94% | 3.33 M | $189.88 |
| Q1 2018 | -364,833 | Reduce 10.96% | 2.96 M | $206.46 |
| Q2 2018 | -416,142 | Reduce 14.05% | 2.55 M | $207.14 |
| Q3 2018 | -336,659 | Reduce 13.22% | 2.21 M | $244.08 |
| Q4 2018 | -1.03 M | Reduce 46.75% | 1.18 M | $223.79 |
| Q1 2019 | -196,252 | Reduce 16.68% | 980,589 | $273.72 |
| Q2 2019 | -430,025 | Reduce 43.85% | 550,564 | $293.68 |
| Q3 2019 | -81,048 | Reduce 14.72% | 469,516 | $291.27 |
| Q4 2019 | -261,404 | Reduce 55.68% | 208,112 | $324.87 |
| Q1 2020 | -208,112 | Sold Out | 208,112 | $0.00 |
| Q2 2020 | +81,555 | New Buy | 81,555 | $362.34 |
| Q3 2020 | -81,555 | Sold Out | 81,555 | $0.00 |
| Q2 2025 | +100,000 | New Buy | 100,000 | $405.46 |
| Q3 2025 | +182,941 | Add 182.94% | 282,941 | $485.02 |
Larry Robbins's Thermo Fisher Scientific Investment FAQs
Larry Robbins first purchased Thermo Fisher Scientific Inc. (TMO) in Q2 2013, acquiring 8,508,661 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Larry Robbins has held Thermo Fisher Scientific Inc. (TMO) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Larry Robbins's largest addition to Thermo Fisher Scientific Inc. (TMO) was in Q2 2013, adding 8,508,661 shares worth $720.09 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Larry Robbins's firm, Glenview Capital Management, LLC, owns 282,941 shares of Thermo Fisher Scientific Inc. (TMO), valued at approximately $137.23 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Thermo Fisher Scientific Inc. (TMO) represents approximately 3.05% of Larry Robbins's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Larry Robbins's peak holding in Thermo Fisher Scientific Inc. (TMO) was 11,387,265 shares, as reported at the end of Q4 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.